Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku

Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody program, BTT-1023. The decision also nixes Seikagaky’s option for Biotie’s VAP-1 SSAO small molecule inhibitors. Biotie had granted Seikagaku exclusive development and commercialization rights in Japan, Taiwan, Singapore, New Zealand, and Australia in April 2003, and the arrangement was built [...]